Drug Profile
Research programme: human papillomavirus vaccines - Redbiotec
Alternative Names: RBT 201; RBT 202Latest Information Update: 14 Feb 2017
Price :
$50
*
At a glance
- Originator Redbiotec
- Class Papillomavirus vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Human papillomavirus infections
Most Recent Events
- 14 Feb 2017 No development reported - Preclinical for Human papillomavirus infections in Switzerland (Parenteral)
- 17 Jan 2012 This programme is still in active development
- 07 Oct 2008 Preclinical trials in Human papillomavirus infections in Switzerland (Parenteral)